Black Patients Have Similar Immune Checkpoint Inhibitor Effectiveness, Lower Toxicity
Black patients have longer time to treatment discontinuation, similar time to next treatment, slightly improved overall survival than White patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.